EUCTR2015-003198-14-GB进行中（未招募）1 期
A multicenter, randomized, double-blind, placebo-controlled, parallel study to investigate the efficacy and safety of multiple oral doses of tasimelteon and matching placebo in travelers with Jet Lag Disorder - VP-VEC-162-3106 Tasimelteon in travellers with jet lag disorder
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 400
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1. Ability and acceptance to provide written informed consent
- •2. Men or women between 18 – 75 years, inclusive
- •3. Body Mass Index (BMI) of = 18 and = 30 kg/m2 (BMI = weight (kg)/ [height (m)]2)
- •4. Males, non-fecund females (i.e., surgically sterilized, if procedure was done 6 months before screening or subject is postmenopausal, without menses for 6 months before screening), or females of child-bearing potential using an acceptable method of birth control (i.e., condoms, diaphragm, spermicidal agents, cervical cap) for a period of 35 days before the first dosing, during the study and for one month after the last dose and must have a negative pregnancy test at the screening and baseline and D1 visits;
- •5. Note: Women using hormonal methods of birth control must use an additional method of birth control during the study and for one month after the last dose. Valid passport for international travel and fluent in English
- •6. In good health as determined by a medical and psychiatric history, physical examination, Electrocardiogram, and serum chemistry and hematology
- •7. Willing to comply with study procedures and restrictions with fixed sleep time and wake time during the study and to attend regularly scheduled clinic visits as specified in this protocol
- •8. Has negative urine test result for selected substances of abuse at V2- through the end of the randomization phase
- •9. Has not used pharmacological sleep assistance more than 4 times/month during the 3 months prior to screening
- •10. Must have discontinued use of all pharmacological sleep aids beginning 1 week prior to Visit 2 and for the duration of the trial
- •11. Must have a target daily bedtime that on average occurs between 21:00 and 24:00
- •12. History of sleep disturbances associated with jet lag symptoms at least once in the last five years, as defined in the International Classification of Sleep Disorders (ICSD-3)
- •13. Must have =60% Sleep Efficiency during the first two thirds of the 8-hour sleep period after a 5-8 hour phase advance of their sleep-wake schedule conducted during a diagnostic PSG while in screening
- •14. Actigraphy must demonstrate, on average, that the total sleep time each night is between 7 to 9 hours during screening
- •15. Actigraphy must demonstrate, on average, the subject’s habitual bedtime does not differ by more than 2 hours during screening
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 200
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 200
排除标准
- •1. History of primary insomnia or any circadian rhythm sleep disorder, other than jet lag, as defined by ICSD-3
- •2. History (within the 12 months prior to screening) of psychiatric disorders including Major Depressive Disorder, Generalized Anxiety Disorder, Axis II Disorders, delirium or any other psychiatric disorder that in the opinion of the clinical investigator would affect participation in the study or full compliance with study procedures
- •3. Current clinically significant cardiovascular, respiratory, neurologic, hepatic, hematopoietic, renal, gastrointestinal or metabolic dysfunction unless currently controlled and stable
- •4. History of intolerance and/or hypersensitivity to melatonin or melatonin agonists
- •5. Indication of impaired liver function (values for enzymes aspartate transaminase (AST) and alanine transaminase (ALT) or bilirubin > Upper Limit of Normal)
- •6. Clinically significant deviation from normal in clinical laboratory results, vital signs measurements, or physical examination findings at screening or baseline as determined by the clinical investigator
- •7. Major surgery, trauma (including broken pelvis/legs), illness (e.g. sepsis, stroke) or immobile for 3 or more days within the past month
- •8. Current smoker or quit smoking within the last 30 days
- •9. Active cancer or cancer treatment within the past 6 months
- •10. Central venous catheter in place or within the past month
- •11. History of pulmonary embolism /deep vein thrombosis (DVT) or short term blood thinner treatment as an outpatient (e.g. Coumadin, Lovenox, heparin)
- •12. History or family history of thrombosis or hypercoagulable state (e.g. Factor V Leiden, Factor VIII deficiency, Protein C & S deficiency)
- •13. Pregnancy or recent pregnancy (within 6 weeks)
- •14. History of restless leg syndrome, sleep apnea, or periodic limb movement disorder and or have current diagnosis as confirmed by the diagnostic PSG at V2
- •15. Habitual bedtime varies by more than two hours, on average
- •16. History or evidence of excessive daytime sleepiness as determined by a score of more than 10 on the Epworth Sleepiness Scale;
- •17. History of drug or alcohol abuse as defined in DSM-V, Diagnostic Criteria for Drug and Alcohol Abuse, within the 12 months prior to screening and/or regular consumption of alcoholic drinks (> 2 drinks/day or > 14 drinks/week)
- •18. Traveled more than three time zones 2 weeks prior to the screening visit until the travel period.
- •19. Traveled outside the origination time zone within 1 week before the end of the screening period.
- •20. An average bedtime that varies more than 2 hours per week than the target bedtime during the weeks between the diagnostic PSG and the baseline visit based on patient reported sleep diaries and actigraphy.
- •21. Worked night, rotating, or split (period of work, followed by break, and then return to work) shift work within 1 month of the screening visit.
- •22. Participation in a previous tasimelteon (aka VEC-162 or BMS-214778) trial
- •23. Use of any investigational drug, including placebo, central nervous system medication, or any other prescription or OTC medication tha
研究者
相似试验
招募中
3 期
A Phase 3 study of remibrutinib in the treatment ofchronic spontaneous urticaria in adults inadequately controlled by H1-antihistaminesCTRI/2022/02/040702ovartis Healthcare Pvt Ltd
进行中（未招募）
1 期
Study of efficacy and safety of secukinumab 2 mL pre-filled syringe (300 mg) in subjects with moderate to severe plaque psoriasisPlaque psoriasisEUCTR2015-005170-38-BEovartis Pharma Services AG210
进行中（未招募）
1 期
Efficacy, safety and tolerability of Serelaxin when added to standard therapy in acute heart failureEUCTR2013-001498-25-IEovartis Pharma Services AG6,800
进行中（未招募）
1 期
A clinical study to evaluate iloperidone in the treatment of patients with acute manic episodes associated with Bipolar I DisorderEUCTR2020-000405-83-PLVanda Pharmaceuticals Inc.400
已完成
不适用
HVTN 705/VAC89220HPX2008PACTR201705002290492Janssen Vaccines & Prevention B.V.2,600